A bill to amend section 845 of title 18, United States Code, relating to explosives, to grant the Attorney General exemption authority.

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors.

Client expense: $176,190 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator. Support expanded screening for Osteoporosis for both women and men under new coverage rules. Support nomination of Peter Pitts for the Patient-Centered Outcomes Research Institute Board of Governors.

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator.

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans. Support Efforts to Eliminate "Lifetime Caps" on health insurance benefits. Support Part D Medicare Coverage Gap Discount Program "draft guidance" to improve the program for beneficiaries. Oppose Recess Appointment of Dr. Donald Berwick as CMS Administrator.

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.

Client expense: $175,137 · Firm income: Not reported

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.

Client expense: Not reported · Firm income: $12,701

H.R. 1548 - Pathway for Biosimilars Act Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Support patient-centered comparative effectiveness research language passed by the Senate in H.R. 3590 Support 340B Federal Drug Discount Program purchasing provisions passed by the House and Senate in H.R. 3590 Oppose all efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs Support "Specialty Tier" pricing relief in Medicare Part D Drug Plans and in CMS rulemaking regarding those plans. Support increased funding to address the growing national burden of arthritis, including intervention and prevention plans.

Client expense: Not reported · Firm income: $25,403

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200 and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills

Client expense: $115,362 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Oppose efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs

Client expense: $164,909 · Firm income: Not reported

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills Support request for House Oversight Committee hearings on prostate cancer, additional efforts to screen for and treat Oppose the establishment of a "Super MedPAC" Commission empowered to cut Medicare payments and benefits Oppose the Medicare cuts included in H.R. 3200, H.R. 3962, H.R. 3590, and all health care reform measures Oppose Senate Amendment 2793 Support McCain Motion to Recommit H.R. 3590 with instructions to remove all Medicare cuts Support Senate Amendment 2942 Support H.R. 3790 Support H.R. 2115 Oppose efforts to shorten the 12-year exclusivity period provided (in both the House and Senate health care reform bills) for the original biologic drug as it pertains to a safe pathway for biosimilar "follow-on" drugs

Client expense: Not reported · Firm income: $26,618

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200 and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills

Client expense: $115,362 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions in H.R. 3200 and all health care reform measures H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769 Support Eshoo/Barton Amendment on biosimilars (to H.R. 3200) in House Energy and Commerce Committee Support increased Osteoporosis screening funds in health care reform bills

Client expense: Not reported · Firm income: $18,893

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

Issues related to the regulation of consumer financial products, including S. 566 (the Financial Product Safety Commission Act) and H.R. 1705 (companion legislation to S. 566); Issues involving payment cards, interchange fees, and card issuer practices, including H.R. 2382 (the Credit Card Interchange Fees Act), H.R. 2695 (the Credit Card Fair Fee Act), S. 1212 (the Credit Card Fair Fee Act), S. 414 (the Credit Card Accountability Responsibility and Disclosure Act), H.R. 627 (the Credit Cardholders Bill of Rights Act), S. 325 (the Credit Cardholders Bill of Rights Act), S. 392 (the Credit Card Reform Act), S. 399 (the Universal Default Prohibition Act), H.R. 1456 (the Consumer Overdraft Protection Fair Practices Act), H.R. 1608 (the Protecting Consumers from Unreasonable Credit Rates Act) and S. 500 (companion legislation to H.R. 1608), H.R. 1610 (the Interest Rate Equity Act), H.R. 2007 (the American Credit Card Reform Act), S. 710 (the Fair Gift Card Act), S. 165 (the Student Credit Card Protection Act), S. 900 (the Credit Card Safety Star Act), and provisions in H.R. 3170 (the Financial Services and General Government Appropriations Act); Issues pertaining to data security, security breach notification, and mitigation of harm resulting from security breaches, including H.R. 2221 (the Data Accountability and Trust Act), S. 139 (the Data Breach Notification Act), and S. 1070 (a bill to establish the Small Business Information Security Task Force); Issues involving the bankruptcy code, including S. 257 (the Consumer Credit Fairness Act); Issues related to federal agency enforcement authority, including H.R. 2309 (the Consumer Credit and Debt Protection Act); and market access issues in global markets. Issues related to the use of payment cards in connection with the purchase of prescription medications over the Internet, including provisions in S. 525 (the Pharmaceutical Market Access and Drug Safety Act) and H.R. 1298 (companion legislation to S. 525); Issues related to the regulation of Internet gambling, including H.R. 2266 (the Reasonable Prudence in Regulation Act), H.R. 2267 (the Internet Gambling Regulation, Consumer Protection, and Enforcement Act), and H.R. 2268 (the Internet Gambling Regulation and Tax Enforcement Act);

Issues involving payment cards, interchange fees, and card issuer practices, including H.R. 2382 (the Credit Card Interchange Fees Act), H.R. 2695 (the Credit Card Fair Fee Act), S. 1212 (the Credit Card Fair Fee Act), S. 414 (the Credit Card Accountability Responsibility and Disclosure Act), H.R. 627 (the Credit Cardholders Bill of Rights Act), S. 325 (the Credit Cardholders Bill of Rights Act), S. 392 (the Credit Card Reform Act), S. 399 (the Universal Default Prohibition Act), H.R. 1456 (the Consumer Overdraft Protection Fair Practices Act), H.R. 1608 (the Protecting Consumers from Unreasonable Credit Rates Act) and S. 500 (companion legislation to H.R. 1608), H.R. 1610 (the Interest Rate Equity Act), H.R. 2007 (the American Credit Card Reform Act), S. 710 (the Fair Gift Card Act), S. 165 (the Student Credit Card Protection Act), S. 900 (the Credit Card Safety Star Act), and provisions in H.R. 3170 (the Financial Services and General Government Appropriations Act); issues involving the bankruptcy code, including S. 257 (the Consumer Credit Fairness Act); issues related to the regulation of consumer financial products, including S. 566 (the Financial Product Safety Commission Act) and H.R. 1705 (companion legislation to S. 566); issues pertaining to data security, security breach notification, and mitigation of harm resulting from security breaches, including H.R. 2221 (the Data Accountability and Trust Act), S. 139 (the Data Breach Notification Act), and S. 1070 (a bill to establish the Small Business Information Security Task Force); issues related to the use of payment cards in connection with the purchase of prescription medications over the Internet, including provisions in S. 525 (the Pharmaceutical Market Access and Drug Safety Act) and H.R. 1298 (companion legislation to S. 525); issues related to the regulation of Internet gambling, including H.R. 2266 (the Reasonable Prudence in Regulation Act), H.R. 2267 (the Internet Gambling Regulation, Consumer Protection, and Enforcement Act), and H.R. 2268 (the Internet Gambling Regulation and Tax Enforcement Act); issues related to federal agency enforcement authority, including H.R. 2309 (the Consumer Credit and Debt Protection Act); and market access issues in global markets.

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769

Client expense: $132,507 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

H.R. 1548 - Pathway for Biosimilars Act H.R. 2 - Oppose Physician-Owned Hospital restrictions H.R. 756/ S.660 - Support National Pain Care Policy Act of 2009 Oppose use of comparative effectiveness research to determine health care coverage or reimbursement decisions Support Health IT funding and standards Support Hagen/Enzi/Hatch Amendment to S. 325 Support HR 1894 and S. 769

Client expense: Not reported · Firm income: $14,675

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR)

Issues involving interchange fees and card issuer practices, including provisions in S. 414 (the Credit Card Accountability Responsibility and Disclosure Act), H.R. 627 (the Credit Cardholders Bill of Rights Act), S. 325 (the Credit Cardholders Bill of Rights Act), S. 392 (the Credit Card Reform Act), S. 399 (the Universal Default Prohibition Act), H.R. 1456 (the Consumer Overdraft Protection Fair Practices Act), S. 710 (the Fair Gift Card Act), and S. 165 (the Student Credit Card Protection Act). Issues pertaining to regulations issued pursuant to section 626 of H.R. 1105 (the Omnibus Appropriations Act) regarding enforcement authority; issues related to the regulation of consumer financial products, including S. 566 (the Financial Product Safety Commission Act), and H.R. 1705 (companion legislation to S. 566). Issues pertaining to data security, security breach notification, and mitigation of harm resulting from security breaches, including provisions in S. 139 (the Data Breach Notification Act). Issues related to implementation of the withholding requirements under section 3402(t) of the Internal Revenue Code (Code), including H.R. 275 (a bill to repeal section 3402(t) of the Code) and section 1511 of H.R. 1 (the American Recovery and Reinvestment Act). Issues related to the use of payment cards in connection with the purchase of prescription medications over the Internet, including provisions in S. 525 (the Pharmaceutical Market Access and Drug Safety Act) and H.R. 1298 (companion legislation to S. 525). Issues related to market access in global markets.

Client expense: $620,000 · Firm income: Not reported

Issues involving interchange fees and card issuer practices, including provisions in S. 414 (the Credit Card Accountability Responsibility and Disclosure Act), H.R. 627 (the Credit Cardholders Bill of Rights Act), S. 325 (the Credit Cardholders Bill of Rights Act), S. 392 (the Credit Card Reform Act), S. 399 (the Universal Default Prohibition Act), H.R. 1456 (the Consumer Overdraft Protection Fair Practices Act), S. 710 (the Fair Gift Card Act); S. 165 (the Student Credit Card Protection Act); issues pertaining to regulations issued pursuant to section 626 of H.R. 1105 (the Omnibus Appropriations Act) regarding enforcement authority; issues related to the regulation of consumer financial products, including S. 566 (the Financial Product Safety Commission Act) and H.R. 1705 (companion legislation to S. 566); issues pertaining to data security, security breach notification, and mitigation of harm resulting from security breaches, including provisions in S. 139 (the Data Breach Notification Act); issues related to implementation of the withholding requirements under section 3402(t) of the Internal Revenue Code (Code), including H.R. 275 (a bill to repeal section 3402(t) of the Code) and section 1511 of H.R. 1 (the American Recovery and Reinvestment Act); issues related to the use of payment cards in connection with the purchase of prescription medications over the Internet, including provisions in S. 525 (the Pharmaceutical Market Access and Drug Safety Act) and H.R. 1298 (companion legislation to S. 525); and market access issues in global markets.

Client expense: Not reported · Firm income: $220,000